Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) EBITDA (2016 - 2025)

IGC Pharma has reported EBITDA over the past 16 years, most recently at -$1.8 million for Q3 2025.

  • Quarterly EBITDA fell 6.24% to -$1.8 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$6.5 million through Sep 2025, up 48.44% year-over-year, with the annual reading at -$7.2 million for FY2025, 45.14% up from the prior year.
  • EBITDA was -$1.8 million for Q3 2025 at IGC Pharma, down from -$1.6 million in the prior quarter.
  • Over five years, EBITDA peaked at -$1.2 million in Q1 2025 and troughed at -$6.7 million in Q1 2022.
  • The 5-year median for EBITDA is -$2.4 million (2024), against an average of -$2.8 million.
  • Year-over-year, EBITDA crashed 185.41% in 2021 and then skyrocketed 66.85% in 2024.
  • A 5-year view of EBITDA shows it stood at -$2.3 million in 2021, then decreased by 0.26% to -$2.3 million in 2022, then tumbled by 141.17% to -$5.6 million in 2023, then skyrocketed by 66.85% to -$1.8 million in 2024, then rose by 0.38% to -$1.8 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's EBITDA are -$1.8 million (Q3 2025), -$1.6 million (Q2 2025), and -$1.2 million (Q1 2025).